The Optimal Route of Administration of the Glycoprotein IIb/IIIa Receptor Antagonist Abciximab During Percutaneous Coronary Intervention; Intravenous Versus Intracoronary.

Curr Cardiol Rev · 2008 · PMC2801861 · PMID 20066137

Europe PMC DOI

hedged sentence

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

borderline significantP=0.08so close (0.05 < p ≤ 0.1)

When comparing the composite end-point of MI and death a borderline significant difference between ic and iv group was found (6% vs . 14%, P=0.08).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.